TroVax in colorectal cancer

Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases

(2013) Natasa Strbo et al.   IMMUNOLOGIC RESEARCH

Treatment of Metastatic Colon Cancer: “The Times They Are A-Changing”

(2013) Nancy E. Kemeny   JOURNAL OF CLINICAL ONCOLOGY

Long-term survival after hepatic and pulmonary resection of colorectal cancer metastases

(2013) Isabelle Sourrouille et al.   JOURNAL OF SURGICAL ONCOLOGY

Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial

(2013) Orin Bloch et al.   NEURO-ONCOLOGY

Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4

(2013) Rabih Said et al.   Frontiers in Oncology

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

(2012) Don G. Morris et al.   INVESTIGATIONAL NEW DRUGS

The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: A systematic review

(2012) Douglas Quan et al.   SURGERY

Viral Vector-Based Therapeutic Cancer Vaccines

(2011) Cecilia Larocca et al.   CANCER JOURNAL

TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development

(2011) Dae Won Kim et al.   Human vaccines & immunotherapeutics

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings

(2010) Stéphane Oudard et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer

(2010) Rodryg Ramlau et al.   Journal of Thoracic Oncology

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax)

(2009) Robert J. Amato et al.   JOURNAL OF IMMUNOTHERAPY

Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α

(2009) Robert E. Hawkins et al.   JOURNAL OF IMMUNOTHERAPY

Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)

(2009) Robert J. Amato et al.   JOURNAL OF IMMUNOTHERAPY

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

(2009) Howard L Kaufman et al.   Journal of Translational Medicine

Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial

(2008) R. J. Amato et al.   CLINICAL CANCER RESEARCH

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

(2008) R. Dreicer et al.   INVESTIGATIONAL NEW DRUGS

An MVA-based Vaccine Targeting the Oncofetal Antigen 5T4 in Patients Undergoing Surgical Resection of Colorectal Cancer Liver Metastases

(2008) Eyad Elkord et al.   JOURNAL OF IMMUNOTHERAPY